A Phase 1b/2 Study of OMP-59R5 (Tarextumab) in Combination With Etoposide and Platinum Therapy

Clinical trial NCT01859741 · TERMINATED

Trial details

NCT number: NCT01859741
Sponsor: OncoMed Pharmaceuticals, Inc.
Status: TERMINATED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Stage IV Small Cell Lung Cancer

Start date: 2012-01-07
Primary completion: 2017-04-18
Enrollment: 172

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.